What We Do

We discover and develop innovative drug products for treatment of cardio-metabolic diseases. Using our expertise in amino-lipid chemistry, we transform approved drugs or previously studied, biologically active agents to potentially make them better for patients.

 

Pipeline

» TP-113 for type 2 diabetes

» TP-452 for high LDL cholesterol

» TP-252 for very high triglycerides

» TP-8252 for mixed dyslipidemia

 
Learn more about our pipeline. »»

News

April 29, 2015
Thetis Pharmaceuticals Presents Preclinical Data on Novel Oral Agent for Type 2 Diabetes

March 4, 2015
Notice of Allowance on Composition of Matter Patent Expanding Type 2 Diabetes Portfolio

January 19, 2015
Thetis Initiates Diabetes Reversal Study On Metformin-DHA Agent

January 5, 2015
Pharma Industry Veteran Richard Daly Joins Thetis As Commercial Advisor